Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BFRI NASDAQ:CING NASDAQ:CMRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFRIBiofrontera$0.80-19.1%$0.97$0.54▼$1.19$9.61M0.89201,382 shs398,556 shsCINGCingulate$4.57+4.1%$6.23$3.20▼$11.89$55.99M-0.81496,472 shs458,412 shsCMRAComera Life Sciences$0.00$0.00▼$0.00$3K1.061,192 shsN/A7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFRIBiofrontera0.00%-30.43%-25.93%+2.56%+14.45%CINGCingulate0.00%-13.28%-13.12%-23.83%+7.53%CMRAComera Life Sciences0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFRIBiofrontera$0.80-19.1%$0.97$0.54▼$1.19$9.61M0.89201,382 shs398,556 shsCINGCingulate$4.57+4.1%$6.23$3.20▼$11.89$55.99M-0.81496,472 shs458,412 shsCMRAComera Life Sciences$0.00$0.00▼$0.00$3K1.061,192 shsN/A7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFRIBiofrontera0.00%-30.43%-25.93%+2.56%+14.45%CINGCingulate0.00%-13.28%-13.12%-23.83%+7.53%CMRAComera Life Sciences0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBFRIBiofrontera 2.00Hold$2.75243.75% UpsideCINGCingulate 2.33Hold$34.50654.92% UpsideCMRAComera Life Sciences 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CING, BFRI, and CMRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2026BFRIBiofrontera Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/27/2026BFRIBiofrontera Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/20/2026CINGCingulate Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/8/2026CINGCingulate Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$58.00 ➝ $55.003/23/2026CINGCingulate Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$16.00 ➝ $14.00(Data available from 5/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBFRIBiofrontera$41.71M0.23N/AN/A$0.90 per share0.89CINGCingulateN/AN/AN/AN/A$0.31 per shareN/ACMRAComera Life Sciences$1.00M0.00N/AN/AN/ANaNCompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBFRIBiofrontera-$10.54M-$0.97N/A13.33N/A-25.66%-1,112.63%-56.06%N/ACINGCingulate-$22.45M-$4.23N/AN/AN/AN/A-723.31%-212.87%N/ACMRAComera Life Sciences-$18M-$0.31N/AN/AN/AN/AN/AN/AN/ALatest CING, BFRI, and CMRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026BFRIBiofrontera-$0.1150-$0.41-$0.2950-$0.41$10.25 million$10.08 million5/14/2026Q1 2026CINGCingulate-$0.53-$0.95-$0.42-$0.95N/AN/A3/19/2026Q4 2025BFRIBiofrontera$0.29$0.50+$0.21$0.47$16.15 million$17.10 million3/18/2026Q4 2025CINGCingulate-$0.56-$0.84-$0.28-$0.84N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBFRIBiofronteraN/AN/AN/AN/AN/ACINGCingulateN/AN/AN/AN/AN/ACMRAComera Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBFRIBiofrontera0.441.521.40CINGCingulate0.461.161.16CMRAComera Life SciencesN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBFRIBiofrontera10.08%CINGCingulate41.31%CMRAComera Life SciencesN/AInsider OwnershipCompanyInsider OwnershipBFRIBiofrontera4.80%CINGCingulate4.33%CMRAComera Life Sciences8.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBFRIBiofrontera7012.01 million11.43 millionNo DataCINGCingulate2012.25 million11.72 millionNot OptionableCMRAComera Life Sciences230.74 million28.00 millionNot OptionableCING, BFRI, and CMRA HeadlinesRecent News About These CompaniesTandy Leather Factory (NASDAQ:TLF) Stock Quotes, Forecast and News SummaryOctober 8, 2024 | benzinga.comCarisma Therapeutics to Join Citizens JMP Life Sciences ConferenceMay 12, 2024 | msn.comComera Life Sciences Announces Sweeping Workforce TerminationJanuary 31, 2024 | msn.comComera Life Sciences Announces Bridge Financing and Exercise of Take Private OptionJanuary 4, 2024 | finance.yahoo.comComera Life Sciences Announces Bridge Financing and Exercise of Take Private OptionJanuary 4, 2024 | finance.yahoo.comComera Life Sciences to explore strategic alternativesDecember 6, 2023 | msn.comComera Life Sciences Announces Process Exploring Strategic AlternativesDecember 6, 2023 | finance.yahoo.comComera Life Sciences Stock (NASDAQ:CMRA), Analyst Ratings, Price Targets, PredictionsNovember 26, 2023 | benzinga.comComera Life Sciences Holdings Inc [CMRA] stock for 1,049,897 USD was acquired by Cherington CharlesNovember 17, 2023 | knoxdaily.comKComera Life Sciences Designates Dorothy Clarke to Board of DirectorsNovember 13, 2023 | finance.yahoo.comComera Life Sciences Appoints Dorothy Clarke to Board of DirectorsNovember 13, 2023 | finance.yahoo.comComera Life Sciences GAAP EPS of -$0.10, revenue of $0.14MNovember 9, 2023 | msn.comComera Life Sciences Reports Financial Results for Third Quarter 2023 and Recent Business HighlightsNovember 9, 2023 | finance.yahoo.comComera Life Sciences Holdings Inc [CMRA] Insider Activity: An Update for InvestorsNovember 8, 2023 | knoxdaily.comKInvesting in Comera Life Sciences Holdings Inc (CMRA): What You Must KnowOctober 18, 2023 | knoxdaily.comKComera Life Sciences Advancing Subcutaneous Monoclonal Antibody FormulationsOctober 18, 2023 | finance.yahoo.comComera Life Sciences Presents SQore™ Platform Technology Data at PODD: Partnerships in Drug Delivery ConferenceOctober 16, 2023 | finance.yahoo.comComera Life Sciences Holdings Inc [CMRA] 10% Owner makes an insider purchase of 2,053,789 shares worth 1.05 million.October 13, 2023 | knoxdaily.comKMassive Insider Trade At Comera Life SciencesSeptember 13, 2023 | benzinga.com10% Owner At This Health Care Company Buys $1.05M of StockSeptember 12, 2023 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe DRAM Shake-Up: Samsung Stumbles, Micron Chases $1000By Jeffrey Neal Johnson | May 12, 2026Insider Sales: Top AST SpaceMobile Insider Cuts Postion Over 30%By Leo Miller | May 6, 2026$39 Trillion Debt Signal: 3 TIPS ETFs to Hedge Persistent InflationBy Chris Markoch | April 19, 2026Churchill Downs: The Derby Is Just the BeginningBy Chris Markoch | April 24, 2026Intuitive Surgical's Selloff Sets Up a 30% Rebound OpportunityBy Thomas Hughes | April 23, 2026CING, BFRI, and CMRA Company DescriptionsBiofrontera NASDAQ:BFRI$0.80 -0.19 (-19.08%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$0.80 0.00 (-0.38%) As of 05/15/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.Cingulate NASDAQ:CING$4.57 +0.18 (+4.10%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$4.63 +0.06 (+1.29%) As of 05/15/2026 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.Comera Life Sciences NASDAQ:CMRAComera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Peloton Stock Gives Back Gains After Upbeat Earnings Report MarketBeat Week in Review – 05/11 - 05/15 Datavalut Gains Traction: 5 Reasons to Sell Now TMC Stock: Why This Pre-Revenue Miner Is Worth Watching Alphabet's Googlebook Brings Gemini AI to PC Hardware As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In Robinhood, SoFi, and Webull Are Telling Very Different Stories Viking Sails to All-Time Highs—Fundamentals Signal More to Come Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
